Get started
Author

Richard J. Honeywell

Observed names: Honeywell, R. J., Honeywell, R.J., Honeywell, Richard J., Honeywell, Richard James, R Honeywell, R. HONEYWELL, R. Honeywell, R. J. Honeywell, R.J. Honeywell, RG Honeywell, Richard Honeywell, Richard J Honeywell
Observed institutions: University of Pisa, Roswell Park Comprehensive Cancer Center, University Medical Center Groningen, Harvard University, Johns Hopkins University, Technion – Israel Institute of Technology, Pfizer (United States), Max Delbrück Center, Maastricht University Medical Centre, Southampton General Hospital, Paul Scherrer Institute, Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute, Massachusetts General Hospital, Taiho Pharmaceutical (Japan), Taiho Oncology (United States), Stanford Medicine, National Cancer Institute, Elisabeth-TweeSteden Ziekenhuis, Amsterdam University Medical Centers, Sidney Kimmel Comprehensive Cancer Center, University of Southampton, Cancer Center Amsterdam, University of Milano-Bicocca, University of Tübingen, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Stanford University
ORCID: 0000-0001-9415-5959
Observed ORCID: 0000-0001-9415-5959
OpenAlex ID: A5020883449
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
2011 · Kristy J. Gotink, Henk J. Broxterman, et al. · Clinical Cancer Research · 361
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
2013 · M Maftouh, A Avan, et al. · British Journal of Cancer · 183
PDF
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
2012 · Amir Avan, Francesco Crea, et al. · Molecular Cancer Therapeutics · 102
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
2010 · R. Honeywell, K. Yarzadah, et al. · Journal of Chromatography B · 98
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
2008 · J. Sigmond, R.J. Honeywell, et al. · Annals of Oncology · 93
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
2013 · Amir Avan, Viola Caretti, et al. · Cancer Research · 88
PDF
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
2010 · Joline S.W. Lind, Anne-Marie C. Dingemans, et al. · Clinical Cancer Research · 83
Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
2018 · Daniel J. De Klerk, Richard J. Honeywell, et al. · Cancers · 62
PDF
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
2011 · C. Tibaldi, E. Giovannetti, et al. · Annals of Oncology · 61
PDF
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
2015 · Kristy J. Gotink, Maria Rovithi, et al. · Cellular Oncology · 60
PDF
Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine
2015 · Richard J. Honeywell, Veronique W.T. Ruiz van Haperen, et al. · The International Journal of Biochemistry & Cell Biology · 56
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
2011 · Auke D. Adema, Kees Smid, et al. · Investigational New Drugs · 53
PDF
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
2007 · Jens Voortman, Egbert F. Smit, et al. · Clinical Cancer Research · 49
PDF
The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry
2006 · R. Honeywell, A.C. Laan, et al. · Journal of Chromatography B · 49
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
2015 · Ittai B Muller, Adrianus J De Langen, et al. · Expert Review of Anticancer Therapy · 44
PDF
DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
2013 · Sanne R. Martens-de Kemp, Simone U. Dalm, et al. · PLoS ONE · 42
PDF
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
2015 · Esther A. Kleibeuker, Matthijs A. ten Hooven, et al. · Cancer Medicine · 40
PDF
Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)
2013 · Godefridus J. Peters, Kees Smid, et al. · Investigational New Drugs · 40
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment
2019 · Beatrice Balboni, Btissame El Hassouni, et al. · Expert Opinion on Investigational Drugs · 37
PDF
Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
2019 · Paul Noordhuis, Adrianus C. Laan, et al. · International Journal of Molecular Sciences · 36
PDF
The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians
2000 · O. O. Akinyinka, A. Sowunmi, et al. · European Journal of Clinical Pharmacology · 36
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR
2015 · Sue Ellen Verbrugge, Marjon Al, et al. · Oncotarget · 35
PDF
Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells
2012 · E. Giovannetti, M. Labots, et al. · Current Pharmaceutical Design · 33
Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
2012 · Lale Erdem, Elisa Giovannetti, et al. · Current Topics in Medicinal Chemistry · 33
Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
2014 · Auke D Adema, Karijn Floor, et al. · SpringerPlus · 32
PDF
Works count: 160
Citation count: 2,561
H-index: 30
I10-index: 58
Year
Topic
Type